Cetera Investment Advisers Acquires 67 Shares of Thermo Fisher Scientific Inc. (TMO)

Cetera Investment Advisers raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.4% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,898 shares of the medical research company’s stock after buying an additional 67 shares during the period. Cetera Investment Advisers’ holdings in Thermo Fisher Scientific were worth $793,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of TMO. Capital Financial Planning LLC acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at $27,000. Hanson McClain Inc. raised its holdings in shares of Thermo Fisher Scientific by 263.9% in the 4th quarter. Hanson McClain Inc. now owns 131 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 95 shares in the last quarter. Truvestments Capital LLC acquired a new stake in Thermo Fisher Scientific during the 1st quarter worth $29,000. Capital Investment Advisory Services LLC acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth $35,000. Finally, Liberty Wealth Management LLC acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth $35,000. 88.39% of the stock is owned by institutional investors.

Several brokerages recently commented on TMO. Robert W. Baird lifted their price target on shares of Thermo Fisher Scientific from $264.00 to $270.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 30th. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $310.00 price target on the stock in a research note on Tuesday, April 9th. BTIG Research lifted their price target on shares of Thermo Fisher Scientific to $310.00 and gave the stock a “buy” rating in a research note on Tuesday, March 26th. Deutsche Bank lifted their price target on shares of Thermo Fisher Scientific from $275.00 to $300.00 and gave the stock a “buy” rating in a research note on Friday, March 22nd. Finally, Argus lifted their price target on shares of Thermo Fisher Scientific from $285.00 to $310.00 and gave the stock a “buy” rating in a research note on Wednesday, May 1st. Two investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Thermo Fisher Scientific presently has an average rating of “Buy” and an average price target of $293.77.

NYSE TMO opened at $265.36 on Wednesday. The company has a current ratio of 1.69, a quick ratio of 1.16 and a debt-to-equity ratio of 0.61. The firm has a market capitalization of $105.16 billion, a price-to-earnings ratio of 23.86, a price-to-earnings-growth ratio of 1.72 and a beta of 1.11. Thermo Fisher Scientific Inc. has a one year low of $202.83 and a one year high of $282.98.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, April 24th. The medical research company reported $2.81 EPS for the quarter, beating analysts’ consensus estimates of $2.74 by $0.07. The company had revenue of $6.13 billion for the quarter, compared to analyst estimates of $6.04 billion. Thermo Fisher Scientific had a net margin of 12.89% and a return on equity of 17.06%. Thermo Fisher Scientific’s quarterly revenue was up 4.6% on a year-over-year basis. During the same period in the previous year, the business posted $2.50 earnings per share. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 12.19 earnings per share for the current year.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 50,713 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $273.21, for a total value of $13,855,298.73. Following the transaction, the chief executive officer now directly owns 302,193 shares in the company, valued at $82,562,149.53. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Gregory J. Herrema sold 19,808 shares of Thermo Fisher Scientific stock in a transaction dated Monday, February 25th. The shares were sold at an average price of $253.29, for a total transaction of $5,017,168.32. Following the completion of the sale, the senior vice president now directly owns 25,688 shares in the company, valued at approximately $6,506,513.52. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 76,320 shares of company stock worth $20,405,269. 0.45% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.baseballdailydigest.com/news/2019/05/22/cetera-investment-advisers-acquires-67-shares-of-thermo-fisher-scientific-inc-tmo.html.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Featured Story: What are the qualifications of a portfolio manager?

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.